Cas9 & Cpf1 secretion
and activity
Difference between revisions of "Template:Team:Utrecht/MainBody"
| Line 2,191: | Line 2,191: | ||
</video> | </video> | ||
| − | <div class="description">The lab can be a treacherous environment. One tiny mistake, and it | + | <div class="description">The lab can be a treacherous environment. One tiny mistake, and it could be your last.. We answer important questions about how to stay safe in the lab.</div> |
</div> | </div> | ||
| Line 3,107: | Line 3,107: | ||
Our team collaborated with the Wageningen team to obtain independent validations of both our and their biobricks. | Our team collaborated with the Wageningen team to obtain independent validations of both our and their biobricks. | ||
<br><br> | <br><br> | ||
| + | <div style="float: right; margin-left: 35px; margin-bottom: 10px;"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/thumb/f/f5/Collab_WUR_UU.jpg/320px-Collab_WUR_UU.jpg"> | ||
| + | <br> | ||
| + | <span class="text-figure"> | ||
| + | Our collaboration with Wageningen has been great fun. | ||
| + | </span> | ||
| + | </div> | ||
Wageningen validated the secreted-Cas9 and secreted-Cpf1 biobricks for us (BB_numbers). | Wageningen validated the secreted-Cas9 and secreted-Cpf1 biobricks for us (BB_numbers). | ||
Members of the Wageningen team came to Utrecht to perform this validation together with members of the Utrecht team in our lab. | Members of the Wageningen team came to Utrecht to perform this validation together with members of the Utrecht team in our lab. | ||
| Line 3,119: | Line 3,126: | ||
We also performed a leucine zipper BiFC measurement, where we transformed split sfGFP and split Venus to E.coli K12 and also full sfGFP and full Venus as controls. | We also performed a leucine zipper BiFC measurement, where we transformed split sfGFP and split Venus to E.coli K12 and also full sfGFP and full Venus as controls. | ||
Cells were then lysed and fluorescence was measured in the cell lysate <a target=_BLANK href="https://2017.igem.org/Team:Wageningen_UR/Collaborations" class="url_external">(link)</a>. | Cells were then lysed and fluorescence was measured in the cell lysate <a target=_BLANK href="https://2017.igem.org/Team:Wageningen_UR/Collaborations" class="url_external">(link)</a>. | ||
| − | |||
| − | |||
| − | |||
<br><br> | <br><br> | ||
| Line 3,130: | Line 3,134: | ||
<br><br> | <br><br> | ||
| − | < | + | |
| + | <center> | ||
| + | <img onclick="openmodal('rivm-event')" style="cursor: pointer;" src="https://static.igem.org/mediawiki/2017/thumb/f/f7/8997_Kennisparade_%281%29.jpg/240px-8997_Kennisparade_%281%29.jpg"> | ||
| + | <br> | ||
| + | <span class="text-figure"> | ||
| + | Attenting a RIVM event. <a href="javascript:void(0)" onclick="openmodal('rivm-event')" style="font-size: 11px;">Click for full size.</a> | ||
| + | </span> | ||
| + | </center> | ||
<br><br> | <br><br> | ||
| Line 3,142: | Line 3,153: | ||
<br><br> | <br><br> | ||
| − | < | + | |
| + | <center> | ||
| + | <img width="100%" src="https://static.igem.org/mediawiki/2017/thumb/b/be/Collab_dusseldorf_postcards.jpg/800px-Collab_dusseldorf_postcards.jpg"> | ||
| + | </center> | ||
</script> | </script> | ||
| Line 3,820: | Line 3,834: | ||
}); | }); | ||
}); | }); | ||
| + | </script> | ||
| + | |||
| + | <script id="modal-rivm-event" type="text/template"> | ||
| + | <img width="650" src="https://static.igem.org/mediawiki/2017/f/f7/8997_Kennisparade_%281%29.jpg"> | ||
</script> | </script> | ||
Revision as of 17:30, 1 November 2017
<!DOCTYPE html>
Comparison of endonuclease activity for Cas9 and Cpf1 that has been produced in, and excreted by, HEK293 cells.
MESA two-component system replication
Details on the MESA two-component system, explanation of its relation to our design and the results of its reproduction.
OUTCASST system production
Detailed explanation of the OUTCASST mechanism, experimental progress and technical prospects.
Modeling and
mathematics
mathematics
Ordinary differential equations, cellular automaton and an object based model for optimal linker-length estimation.
InterLab study participation
Results and details of our measurements for the iGEM 2017 InterLab Study.
Stakeholders & opinions
Interviews and dialogues with stakeholders, potential users, third parties and experts relating to pathogen detection or DNA-based diagnostics.
Risks & safety-issues
Implications and design considerations relating to safety in the usage and implementation of OUTCASST as a diagnostics tool.
Design & integration
OUTCASST toolkit and product design with factors such as bio-safety and user-friendliness taken into account.
Outreach
Videos we made for the dutch public, together with 'de Kennis van Nu'.
Meet our team
About us, our interests and roles in the team and our supervisors.
Sponsors
A listing of our sponsors, how they assisted us and our gratitude for their assistance.
Collaborations
Read about our exchanges with other iGEM teams and government agencies.
Achievements
A short description of all that we have achieved during our participation in the iGEM.
Attributions
A thank-you for everyone that assited us, both in and outside the lab.
×
